Patents by Inventor Morgan Huse

Morgan Huse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MiR200c-EpCAM axis reprogramed immune cells for enhanced anti-tumor function
    Patent number: 12648963
    Abstract: Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress miR200c and/or EpCAM.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: June 9, 2026
    Assignees: Memorial Sloan-Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, Sloan-Kettering Institute for Cancer Research
    Inventors: Morgan Huse, Minggang Zhang
  • MIR200C-EPCAM AXIS REPROGRAMED IMMUNE CELLS FOR ENHANCED ANTI-TUMOR FUNCTION
    Publication number: 20240226161
    Abstract: Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress miR200c and/or EpCAM.
    Type: Application
    Filed: February 18, 2022
    Publication date: July 11, 2024
    Inventors: Morgan HUSE, Minggang ZHANG
  • MIR200C-EPCAM AXIS REPROGRAMED IMMUNE CELLS FOR ENHANCED ANTI-TUMOR FUNCTION
    Publication number: 20240131073
    Abstract: Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising engineered immune cells that overexpress miR200c and/or EpCAM.
    Type: Application
    Filed: February 18, 2022
    Publication date: April 25, 2024
    Inventors: Morgan HUSE, Minggang ZHANG
  • HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF
    Publication number: 20220098329
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., heterodimeric trivalent/tetravalent multispecific antibodies) that specifically bind to three or four distinct target antigens. The immunoglobulin-related compositions described herein are useful in methods for detecting and treating cancer in a subject in need thereof.
    Type: Application
    Filed: November 29, 2019
    Publication date: March 31, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Brian Santich, Nai-Kong V. Cheung, Morgan Huse